NAS:AXSM Key Ratios
| Market Cap $ M | 10,850.69 |
| Enterprise Value $ M | 10,755.52 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | 293.35 |
| Price/Book | 130.28 |
| Price/Sales | 13.61 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 776.00 |
| EPS (TTM) $ | -3.75 |
| Beneish M-Score | -2.88 |
| 10-y EBITDA Growth Rate % | -19.20 |
| 5-y EBITDA Growth Rate % | -8.60 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -57.80 |
| EV-to-EBITDA | -61.07 |
| PEG | -- |
| Shares Outstanding M | 52.38 |
| Net Margin (%) | -24.68 |
| Operating Margin % | -23.55 |
| Pre-tax Margin (%) | -24.61 |
| Quick Ratio | 1.34 |
| Current Ratio | 1.43 |
| ROA % (ttm) | -27.58 |
| ROE % (ttm) | -256.90 |
| ROIC % (ttm) | -84.59 |
| Dividend Yield % | -- |
| Altman Z-Score | 7.44 |
AXSM Number of Guru Trades
AXSM Volume of Guru Trades
Gurus Latest Trades with NAS:AXSM
NAS:AXSM is held by these investors
Axsome Therapeutics Inc Insider Transactions
Guru Commentaries on NAS:AXSM
Axsome Therapeutics Inc. (AXSM) was a new addition to investor portfolios in January of 2025 and has been a positive contributor since. Axsome is a biopharmaceutical company focused on central nervous system conditions such as Alzheimer’s Disease Agitation, Major Depressive Disorder, Migraines, and Fibromyalgia. Their products target a broad range of serious conditions that impact over 150 million people in the United States. Axsome has 4 products commercially available today with 2 others in late stages of approval. These products have the potential to provide over $16 billion in peak sales in comparison to Axsome’s $630 million of revenue in 2025. Auvelity, an oral drug for major depressive disorder, has quickly ramped to over $500 million in sales in 2025. The FDA has given Axsome accelerated review for a label expansion to Alzheimer’s Disease Agitation, which could be a significant catalyst for the stock.
News about NAS:AXSM
Total 0- 1
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
